Live Attenuated Virus Vaccine Against Herpes
- Detailed Technology Description
- A live, attenuated and recombinant Herpes Simplex Virus (HSV) vaccine has been developed. This vaccine has demonstrated effective immunity against both HSV-1 and HSV-2 in mice models.
- Countries
- United States
- Application No.
- PCT/US15/29905
- *Abstract
-
The recombinant HSV contains modifications in particular regions of the UL53 and UL20 genes. In the wild-type virus, glycoprotein K (gK) and UL20 membrane proteins form a complex that interacts with glycoprotein B (gB). The deletions in the N-termini of gK and UL20 disrupt this protein interaction and thus modulate virus-host cell fusion.
Vaccination with the recombinant virus leads to 100% rescue from mortality in mice by both HSV-1 and -2. After vaccination, there was much less viral shedding and no viral DNA in dorsal root ganglia. The mice displayed a full adaptive immune response that protected them from subsequent infection as well as “sterile” immunity, since there was no HSV-1 or HSV-2 viral DNA detected in dorsal ganglia of challenged mice. Protection was associated with high neutralizing antibodies against both viruses and induction of robust cytotoxic T cell responses.
- *IP Issue Date
- None
- *IP Type
- Other Patent
- *Licensing
- Robert J. BrownAssistant DirectorTel: 225-615-8916Email: rjbrown@lsu.edu
- Country/Region
- USA
